MA50862A - Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30 - Google Patents
Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30Info
- Publication number
- MA50862A MA50862A MA050862A MA50862A MA50862A MA 50862 A MA50862 A MA 50862A MA 050862 A MA050862 A MA 050862A MA 50862 A MA50862 A MA 50862A MA 50862 A MA50862 A MA 50862A
- Authority
- MA
- Morocco
- Prior art keywords
- reducing
- methods
- side effects
- conjugate therapy
- body conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Combined Controls Of Internal Combustion Engines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762580261P | 2017-11-01 | 2017-11-01 | |
US201862739635P | 2018-10-01 | 2018-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50862A true MA50862A (fr) | 2020-09-09 |
Family
ID=64557131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050862A MA50862A (fr) | 2017-11-01 | 2018-11-01 | Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20220226439A1 (fr) |
EP (1) | EP3703761A1 (fr) |
JP (2) | JP2021501800A (fr) |
KR (1) | KR20200080274A (fr) |
CN (1) | CN111936170A (fr) |
AU (1) | AU2018359546A1 (fr) |
BR (1) | BR112020008375A2 (fr) |
CA (1) | CA3080799A1 (fr) |
IL (1) | IL274277A (fr) |
MA (1) | MA50862A (fr) |
MX (1) | MX2020004563A (fr) |
SG (1) | SG11202003955UA (fr) |
TW (1) | TW201922285A (fr) |
WO (1) | WO2019089870A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202103342QA (en) * | 2018-10-01 | 2021-04-29 | Seagen Inc | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
CN116940387A (zh) * | 2020-12-03 | 2023-10-24 | 思进股份有限公司 | 使用抗cd30抗体-药物缀合物调节免疫反应 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
WO1991000360A1 (fr) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Reactifs bispecifiques pour le traitement du sida |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
EP0553244B8 (fr) | 1990-10-05 | 2005-06-08 | Celldex Therapeutics, Inc. | Immunostimulation ciblee induite par des reactifs bispecifiques |
EP0557300B1 (fr) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Anticorps bispecifiques, methodes de production et utilisation desdits anticorps |
US5573920A (en) | 1991-04-26 | 1996-11-12 | Surface Active Limited | Antibodies, and methods for their use |
EP1306095A3 (fr) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Méthodes et compositions pour cibler les vaisceaux des tumeurs solides |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
HUE027549T2 (hu) | 2002-07-31 | 2016-10-28 | Seattle Genetics Inc | Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére |
WO2005084390A2 (fr) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Anticorps partiellement charges et procedes de conjugaison desdits anticorps |
EP3545969B1 (fr) | 2009-01-09 | 2023-12-13 | Seagen Inc. | Régimes de dosage pour conjugués de médicaments-anticorps anti-cd30 vc-pab-mmae |
-
2018
- 2018-11-01 AU AU2018359546A patent/AU2018359546A1/en active Pending
- 2018-11-01 US US16/760,916 patent/US20220226439A1/en not_active Abandoned
- 2018-11-01 TW TW107138737A patent/TW201922285A/zh unknown
- 2018-11-01 CN CN201880078567.7A patent/CN111936170A/zh active Pending
- 2018-11-01 EP EP18811409.4A patent/EP3703761A1/fr active Pending
- 2018-11-01 CA CA3080799A patent/CA3080799A1/fr active Pending
- 2018-11-01 KR KR1020207014872A patent/KR20200080274A/ko not_active Application Discontinuation
- 2018-11-01 SG SG11202003955UA patent/SG11202003955UA/en unknown
- 2018-11-01 JP JP2020543732A patent/JP2021501800A/ja not_active Withdrawn
- 2018-11-01 MA MA050862A patent/MA50862A/fr unknown
- 2018-11-01 MX MX2020004563A patent/MX2020004563A/es unknown
- 2018-11-01 WO PCT/US2018/058613 patent/WO2019089870A1/fr unknown
- 2018-11-01 BR BR112020008375-5A patent/BR112020008375A2/pt unknown
-
2020
- 2020-04-27 IL IL274277A patent/IL274277A/en unknown
-
2023
- 2023-08-10 JP JP2023130793A patent/JP2023154026A/ja active Pending
- 2023-08-14 US US18/449,591 patent/US20240245753A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018359546A1 (en) | 2020-05-28 |
TW201922285A (zh) | 2019-06-16 |
CA3080799A1 (fr) | 2019-05-09 |
MX2020004563A (es) | 2020-08-13 |
CN111936170A (zh) | 2020-11-13 |
EP3703761A1 (fr) | 2020-09-09 |
BR112020008375A2 (pt) | 2020-10-06 |
US20220226439A1 (en) | 2022-07-21 |
JP2021501800A (ja) | 2021-01-21 |
US20240245753A1 (en) | 2024-07-25 |
KR20200080274A (ko) | 2020-07-06 |
JP2023154026A (ja) | 2023-10-18 |
IL274277A (en) | 2020-06-30 |
SG11202003955UA (en) | 2020-05-28 |
WO2019089870A1 (fr) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1247922A1 (zh) | 用於治療癌症的吲哚胺2,3-雙加氧酶抑制劑 | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA41463A (fr) | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) | |
WO2016044556A3 (fr) | Inhibiteurs d'arginine méthyltransférase et leurs utilisations | |
WO2015168466A8 (fr) | Inhibiteurs de la déméthylase-1 spécifiques de la lysine | |
EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
MA45054A (fr) | Conjugués médicament-anticorps dll3 pour le traitement de tumeurs à risque de transition neuroendocrinienne | |
LT3609886T (lt) | Benzoazepino analogai kaip brutono tirozinkinazės inhibitoriai | |
MA41159A (fr) | Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques | |
MX2022006862A (es) | Inhibidores duales de magl y faah. | |
IL279609A (en) | Bifunctional compounds for cancer treatment | |
MA50862A (fr) | Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30 | |
IL270927B (en) | fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases | |
MA50767A (fr) | Procédés de réduction des effets secondaires d'une thérapie par conjugués de médicament anticorps anti-cd30 | |
TN2017000448A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease | |
MA46759A (fr) | Dosage de conjugués anticorps-médicament anti-cd30 pour humain non adulte | |
MA51510A (fr) | Procédés de préparation de dérivés d'indolinobenzodiazépine | |
MA49092A (fr) | Compositions et procédés pour la préparation d'acides , -insaturés | |
EP3419644A4 (fr) | Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleur | |
PH12018501076A1 (en) | Compounds for medicinal applications | |
MA44013A (fr) | Machine alimentaire pour la préparation d'aligot | |
GB201808699D0 (en) | Santa's magic bags | |
GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
MA43426A (fr) | Compositions et procédés permettant d'administrer des agents thérapeutiques | |
GB201714241D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies |